Collaborations

17 December 2025   Hesperos announces the establishment of a strategic channel sales and marketing partnership with AsedaSciences, offering its pharmaceutical, cosmetic, nutraceutical and chemical industry clients a powerful combination of human-based, in silico and in vitro tools for development of safer compounds.   Traditionally, compound safety has been assessed using animal testing, but these models raise ethical concerns, lack human physiological relevance, and offer l

24 September 2025   Berkeley-based Prellis Biologics, Inc. , developer of human in vitro antibody generation platform, announces collaboration with Eli Lilly to accelerate the discovery of human antibodies for multiple disease targets.   Prellis’ EXIS™ lymph node platform for target‑specific human antibody generation is a shining example of ingenuity by which several technologies were combined to capture human-relevant physiology.   The traditional method of antibody generat

23 September 2025   Vienna-based Heartbeat.bio , developer of breakthrough therapies for cardiac disorders through its proprietary human-based in vitro cardioid drug discovery platform, announces  it has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies.   Genetic cardiac pathologies such as hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathy, are typically c

16 December 2025   Put in place to accelerate the development of innovative cancer therapies through collaboration initiatives, the Netherlands-based Oncode Accelerator program announces launching of its Demonstrator Project. Through this project, researchers and drug developers will be able to share expertise, experimental platforms, and infrastructure to advance novel therapeutic approaches.   Recent advances in cancer therapies and in particular immunotherapy have produce